Next Article in Journal
The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue
Next Article in Special Issue
Comorbidities and Complications in Idiopathic Pulmonary Fibrosis
Previous Article in Journal
Improving Blood Transfusion Practices in a Community Hospital Setting: Our Experience with Real-Time Clinical Decision Support
Previous Article in Special Issue
Cell Therapy in Idiopathic Pulmonary Fibrosis
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Med. Sci. 2018, 6(3), 68;

Lung Transplantation in Idiopathic Pulmonary Fibrosis

Hospital Universitario Puerta de Hierro de Majadahonda Madrid, 28222 Madrid, Spain
Author to whom correspondence should be addressed.
Received: 19 June 2018 / Revised: 9 August 2018 / Accepted: 10 August 2018 / Published: 23 August 2018
(This article belongs to the Special Issue Idiopathic Pulmonary Fibrosis)
Full-Text   |   PDF [1036 KB, uploaded 23 August 2018]   |  
  |   Review Reports


Despite the advances in recent years in the treatment of idiopathic pulmonary fibrosis (IPF), it continues to be a progressive disease with poor prognosis. In selected patients, lung transplantation may be a treatment option, with optimal results in survival and quality of life. Currently, pulmonary fibrosis is the main cause of lung transplantation. However, mortality on the waiting list of these patients is high, since many patients are referred to the transplant units with advanced disease. There is not a parameter that can predict the survival of a specific patient. Different variables are to be considered in order to decide the right time to send them to a transplant unit. It is also very difficult to decide when to include these patients on the waiting list. Every patient diagnosed with IPF, without contraindications for surgery, should be referred early to a transplant unit for assessment. A uni or bilateral transplantation will be decided based on the characteristics of the patient and the experience of each center. The post-transplant survival of recipients with IPF is lower than that observed in other diseases, such as cystic fibrosis or chronic obstructive pulmonary disease as a consequence of their older age and the frequent presence of associated comorbidity. Post-transplant follow-up must be tight in order to assure optimal level of immunosuppressive treatment, detect complications associated with it, and avoid graft rejection. The main cause of long-term mortality is late graft dysfunction as a consequence of chronic rejection. Other complications, such as infections and tumors, must be considered. View Full-Text
Keywords: lung transplant; idiopathic pulmonary fibrosis; interstitial lung disease lung transplant; idiopathic pulmonary fibrosis; interstitial lung disease

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Laporta Hernandez, R.; Aguilar Perez, M.; Lázaro Carrasco, M.T.; Ussetti Gil, P. Lung Transplantation in Idiopathic Pulmonary Fibrosis. Med. Sci. 2018, 6, 68.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Med. Sci. EISSN 2076-3271 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top